CELPHARMA
ActiveSummary
The computed 12-month bankruptcy probability of CELPHARMA is 1.8% (moderate). The 2025 annual accounts show equity of €1.9m and a net result of €242,673. Its solvency ranks better than 55% of 6,139 sector peers (NACE 46, financial year 2025). The company has been active since 2025 and the Belgian Official Gazette contains no insolvency or warning signals.
Financials · financial year 2025, full format
2025 annual accounts filed late (31 days) Filed on 31 August 2026, deadline 31 July 2026 (7 months after the close on 31 December 2025, Companies Code art. 3:10). Source: NBB, 2026-00473263.
Peer companies
Historical observationOf the 11,280 companies that looked in July 2024 the way this one looks now, 0.7% went bankrupt within 24 months and 96.6% are still going.
- Micro
- under 2 years old
- solvency 30% or more
- a profit of 5% of the balance sheet or more
For this company itself Checked computes a higher bankruptcy probability: 1.8% over twelve months. The score reads more about this company than the group's four characteristics; both figures are right about what they measure.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,475 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74.5% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 11,280 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
| Line | 2025 |
|---|---|
| Remuneration, social security and pensions62 | €181,098 |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €65,358 |
| Other operating charges640/8 | €24,556 |
| Gross operating margin9900 | €635,609 |
| Operating profit (loss)9901 | €364,596 |
| Financial charges65/66B | €42,856 |
| Recurring financial charges65 | €42,856 |
| Profit (loss) for the period before taxes9903 | €321,741 |
| Income taxes67/77 | €79,068 |
| Profit (loss) for the period9904 | €242,673 |
| Transfer to tax-exempt reserves689 | €46,337 |
| Profit (loss) for the period to be appropriated9905 | €196,337 |
| Line | 2025 | |
|---|---|---|
| Assets | ||
| Total assets20/58 | €3.8m | |
| Fixed assets21/28 | €2.3m | |
| Tangible fixed assets22/27 | €1.4m | |
| Land and buildings22 | €1.1m | |
| Plant, machinery and equipment23 | €0.3m | |
| Furniture and vehicles24 | €0.002m | |
| Financial fixed assets28 | €0.9m | |
| Current assets29/58 | €1.5m | |
| Stocks and contracts in progress3 | €0.6m | |
| Stocks30/36 | €0.6m | |
| Amounts receivable within one year40/41 | €0.1m | |
| Trade receivables40 | €0.04m | |
| Other amounts receivable41 | €0.07m | |
| Deferred charges and accrued income490/1 | €0.8m | |
| Equity and liabilities | ||
| Total equity and liabilities10/49 | €3.8m | |
| Equity10/15 | €1.9m | |
| Contributions10/11 | €1.0m | |
| Capital10 | €1.0m | |
| Issued capital100 | €1.0m | |
| Reserves13 | €0.2m | |
| Non-distributable reserves130/1 | €0.01m | |
| Legal reserve130 | €0.01m | |
| Tax-exempt reserves132 | €0.05m | |
| Distributable reserves133 | €0.09m | |
| Profit (loss) carried forward14 | €0.7m | |
| Amounts payable17/49 | €1.9m | |
| Amounts payable after more than one year17 | €1.2m | |
| Financial debts170/4 | €1.2m | |
| Amounts payable within one year42/48 | €0.7m | |
| Current portion of amounts payable after more than one year42 | €0.1m | |
| Financial debts43 | €0.08m | |
| Credit institutions430/8 | €0.08m | |
| Trade debts44 | €0.2m | |
| Suppliers440/4 | €0.2m | |
| Taxes, remuneration and social security45 | €0.03m | |
| Taxes450/3 | €0.009m | |
| Remuneration and social security454/9 | €0.02m | |
| Other amounts payable47/48 | €0.3m | |
| Accrued charges and deferred income492/3 | €211 | |
| Line | 2025 |
|---|---|
| Profit (loss) for the period9904 | €242,673 |
| + Depreciation and write-downs630 | €65,358 |
| Operating cash flow (approximation) | €308,031 |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Filings with the National Bank (1)
| Financial year | Type | Filed | Reference |
|---|---|---|---|
| 31-12-2025 | full format | 31-08-2026 | 2026-00473263 |
Similar companies · same sector, comparable size
Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.